Acceleron Pharma (Acceleron Pharma) Interest Coverage : N/A (As of Sep. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Acceleron Pharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Acceleron Pharma's Operating Income for the three months ended in Sep. 2021 was $-70.6 Mil. Acceleron Pharma's Interest Expense for the three months ended in Sep. 2021 was $0.0 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. Acceleron Pharma Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Acceleron Pharma's Interest Coverage or its related term are showing as below:

XLRN's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 125.655
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Acceleron Pharma Interest Coverage Historical Data

The historical data trend for Acceleron Pharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Acceleron Pharma Interest Coverage Chart

Acceleron Pharma Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Interest Coverage

Get a 7-Day Free Trial

No Debt

N/A

Acceleron Pharma Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Interest Coverage	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Acceleron Pharma's Interest Coverage

For the Biotechnology subindustry, Acceleron Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acceleron Pharma's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acceleron Pharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Acceleron Pharma's Interest Coverage falls into.

Acceleron Pharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Acceleron Pharma's Interest Coverage for the fiscal year that ended in Dec. 2020 is calculated as

Here, for the fiscal year that ended in Dec. 2020, Acceleron Pharma's Interest Expense was $0.0 Mil. Its Operating Income was $-167.3 Mil. And its Long-Term Debt & Capital Lease Obligation was $17.1 Mil.

GuruFocus does not calculate Acceleron Pharma's interest coverage with the available data.

Acceleron Pharma's Interest Coverage for the quarter that ended in Sep. 2021 is calculated as

Here, for the three months ended in Sep. 2021, Acceleron Pharma's Interest Expense was $0.0 Mil. Its Operating Income was $-70.6 Mil. And its Long-Term Debt & Capital Lease Obligation was $12.0 Mil.

GuruFocus does not calculate Acceleron Pharma's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

Acceleron Pharma (NAS:XLRN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Acceleron Pharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of Acceleron Pharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Acceleron Pharma (Acceleron Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

128 Sidney Street, Cambridge, MA, USA, 02139

Website

http://www.acceleronpharma.com

Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.

Executives

Sujay Kango	officer: EVP, Chief Commercial Officer	1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Kevin F Mclaughlin	officer: SVP, CFO and Treasurer	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Adam M Veness	officer: SVP, General Counsel and Sec.	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Thomas A Mccourt	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Habib J Dable	director, officer: CEO and President	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Terrence C Kearney	director	IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Bristol Myers Squibb Co	10 percent owner	430 E. 29TH STREET 14 FLOOR NEW YORK NY 10016
Celgene Corp /de/	10 percent owner	86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Hite	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Jean George	director	CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Kemal Malik	director	C/O ACCELERON PHARMA INC. 128 SIDNEY STREET CAMBRIDGE MA 02139